Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$13.44

-0.037%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$92.12M
EPS-70.5000
P/E Ratio-0.19
Earnings Date08/11/2026

vor

Depreciation and Amortization

Last Annual Value

2.89M

3-Year CAGR

5%

5-Year CAGR

37%

10-Year CAGR

64%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Depreciation and Amortization

VOR · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.89M
-6.1%15.0%N/A 
64.00K
92.3%12.2%-12.9%
0.00
N/AN/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
5.25M
-19.1%-2.5%1.4%
0.00
N/AN/AN/A
-1.13M
N/AN/AN/A
244.00K
-37.9%-22.9%N/A
2.31M
-7.2%-5.2%7.7%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
21.75M
3.7%6.0%N/A
327.00K
4.4%12.6%N/A
362.00K
2.0%25.3%11.4%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.44, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $13.44